Prime Medicine Reports Q2 2026 Results: Cash $108.8M, Runway Into 2027; Pipeline Advances with IND Clearances and BLA Plans
PRME is trading near its 52-week low of $2.67 (14% above the low).
Summary
Prime Medicine reported Q2 2026 results with $108.8M in cash, later reported as $95.1M in the 10-Q, and a runway into 2027, while advancing its gene editing pipeline with IND clearances for PM577a, RMAT designation for PM359, and a planned BLA submission in 1H 2027.
Updated with an SEC 10-Q filing · What changed
Updates
· SEC 10-Q — The 10-Q shows cash and cash equivalents of $47.5M and short-term investments of $47.6M as of June 30, 2026, totaling $95.1M, down from $177.7M at year-end 2025.
Key Events · Earnings and Guidance · PRME
-
Updated · · SEC 10-Q
Q2 2026 Financial Results
Net loss of $42.1M ($0.24/share) on reduced R&D and G&A expenses. Cash, equivalents, and investments totaled $108.8M as of June 30, 2026, down from $191.4M at year-end 2025; the 10-Q shows cash and cash equivalents of $47.5M and short-term investments of $47.6M, totaling $95.1M, down from $177.7M at year-end 2025.
-
Cash Runway Into 2027
Management expects current cash to fund operations into 2027, but the 10-Q filed concurrently includes a going concern warning, highlighting the need for additional capital.
-
PM577a IND and CTA Clearances
FDA cleared the IND in July 2026 and New Zealand Medsafe cleared the CTA in June 2026, establishing a global Phase 1/2 program for Wilson disease. Study startup underway, initial clinical data expected in 2027.
-
PM359 RMAT Designation and BLA Plans
FDA granted Regenerative Medicine Advanced Therapy designation for PM359 in chronic granulomatous disease. Prime Medicine plans a BLA submission in the first half of 2027.
Analysis · PRME · Life Sciences
Prime Medicine disclosed Q2 2026 financials alongside significant pipeline progress. Cash of $108.8 million, later reported as $95.1 million in the 10-Q, provides runway into 2027, but the concurrent 10-Q going concern warning underscores the urgency to raise capital. The company cleared INDs for PM577a in Wilson disease in the U.S. and New Zealand, secured RMAT designation for PM359 in CGD with a BLA submission planned for 1H 2027, and expects to submit an IND for PM647 in AATD in 3Q 2026. The favorable arbitration ruling against Beam Therapeutics removes a key overhang on the AATD program. These updates come at a critical juncture—the company must fund operations beyond 2027, and clinical data readouts in 2027 will be pivotal.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PRME was trading at $3.05 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $556.3M. The 52-week trading range was $2.67 to $6.94. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.